AGC Biologics completed its Copenhagen campus expansion in June 2024 after an investment of roughly $190–200 million.
The expansion added about 19,000 square meters covering manufacturing, quality-control and process-development laboratories, utilities, and warehouse space.
The new building includes eight 2,000-liter single-use mammalian bioreactors and two independent downstream-processing suites, more than doubling the site’s mammalian manufacturing capacity.
The facility can produce approximately 150 additional drug batches annually and has already begun manufacturing a Phase II/III clinical product for its first customer.
The video tour offers an inside look at the new manufacturing floor, laboratory areas, and single-use production technology.
The site received authorization from the Danish Medicines Agency in September 2024, enabling official operations.
Sources:
AGC completes Copenhagen campus expansion
Mammalian and Microbial Manufacturing | Copenhagen
AGC Biologics Completes Copenhagen Campus ...
AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
New Copenhagen Mammalian Manufacturing Building
AGC Biologics Strengthens Portfolio with Latest FDA Commercial Approval at Copenhagen Facility
AGC Biologics breaks ground on USD 190m Danish factory
AGC Biologics Begins Operations in Copenhagen after DMA Approval
Press Releases - AGC Biologics
Christian Christensen's Post - cdmo #agc #biologics
Scientific Interviews & Virtual Facility Tours
AGC plots $194.5M, capacity-doubling upgrade to Copenhagen ...